Global Anti-Hypertensive Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Drug Class (Diuretics, Beta-Blockers, ACI Inhibitors, Calcium Channel Blockers, Combined Alpha And Beta-Blockers, Others), By Type (Primary Hypertension, Secondary Hypertension), By Sales Channel (Prescription, Over-the-counter (OTC)), And By Geography - Forecasts From 2022 To 2027

The global anti-hypertensive drug market is estimated to grow at a CAGR of 3.26% to reach a market size of US$43.585 billion in 2027 from US$34.822 billion in 2020.  

The global anti-hypertensive drug market is poised to surge at a substantial growth over the next five years on account of the growing prevalence of hypertension across the globe due to the unhealthy lifestyles of people. Furthermore, the growing geriatric population is also one of the prime factors anticipated to augment the demand for these drugs, as older adults are considerably more susceptible to high blood pressure than young people. Hypertension is also a major cause of premature deaths worldwide.

The other factors contributing to the prevalence of high blood pressure also include excess smoking, stress, chronic kidney disease, excess alcohol consumption, and obesity.

 All these factors play a crucial role in causing high blood pressure in individuals. Thus, the growing number of smokers and alcohol intake, especially among the millennial population, is anticipated to propel the growth opportunities for the market to expand throughout the forecast period and beyond as the prevalence of hypertension is expected to rise due to these factors. Similarly, the continuously growing proportion of the obese population, along with the growing prevalence of obesity among adults, is expected to drive the demand for these drugs during the coming years.

Furthermore, rapid urbanization and globalization are also factors that are deteriorating the conditions of human health. Also, the changing lifestyle of the people, along with the rising stress level, is driving the demand for hypertension drugs. Moreover, an unhealthy lifestyle in terms of eating and sleeping habits of the people also leads to high blood pressure, which is also anticipated to positively impact the anti-hypertensive drugs market growth during the next five years.

The rising prevalence of hypertension is driving the market growth

One of the major factors significantly driving the demand for these drugs is the globally growing prevalence of hypertension globally. The growing number of smokers, along with the rising proportion of the population with excessive alcohol intake, especially in underdeveloped economies, is boosting the demand for these drugs significantly. According to data from the World Health Organization, there are around 1.13 billion people with hypertension, most of whom live in low and middle-income countries. In addition, the global target of WHO to reduce the prevalence of hypertension by 25% by 2025 is also anticipated to boost the demand for these drugs and add up to the market growth significantly. Additionally, the consumption of these drugs is considered highly necessary as one of the highly focused public health challenges because hypertension increases the risk of cardiovascular disease also. Thus, the drugs for controlling elevated levels of blood pressure reduce the risks of strokes, heart attacks, and also heart failures.

The growing geriatric population is also anticipated to drive the demand

The growth in the geriatric population around to globe is also considered to be one of the key factors which are anticipated to push the demand for anti-hypertensive drugs during the next five years. There is a significant increase in the ageing population, propelling the demand for various drugs as a demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. The major factors responsible for the growing ageing population include increased life expectancy and declining fertility. Also, according to the data provided by the United Nations, the number of people aged 60 or above is expected to reach 20805 million by 2050, from only 962.3 in 2017. In addition, older people are expected to be more susceptible to suffering from high blood pressure, which is expected to propel the demand for these drugs throughout the forecast period and beyond. Moreover, there is a significant increase in the proportion of the geriatric population globally.

The Asia Pacific to show robust growth

Based on geography, the global anti-hypertensive drugs market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The market in the Asia Pacific region is projected to show notable growth during the next five years on account of the rising prevalence of hypertension in developing countries such as India and China due to the high number of smokers and unhealthy lifestyles of the people. In addition, the growing geriatric population in many countries of the APAC region also supports market growth in the coming years.

North America is anticipated to hold a noteworthy share owing to the presence of the state-of-art healthcare sector. Also, the presence of key market players in the region in countries such as the United States and Canada further supports the significant share of this region throughout the forecast period.

Recent Developments

• Due to a probable carcinogen, Pfizer intended to recall blood pressure medications in March 2022. To lower the risk of cardiovascular events, most commonly strokes and myocardial infarctions, the drugs are prescribed for the treatment of hypertension.
• In April 2021, Tyvaso (Treprostinil)., a medication made by United Therapeutics Corporation, was approved by the US Food and Drug Administration to treat pulmonary hypertension brought on by interstitial lung disease.
• Amosartan XQ, a 4-ingredient medication combination for the treatment of hypertension and hyperlipidemia, was introduced by Hanmi Pharmaceuticals in February 2021.
• In December 2020, Quantum Genomics, a biotech company with experience in a class of medications that treat heart failure and hypertension that is difficult to treat, inked a contract with Delpharm for the manufacturing of its future clinical range of firibastat tablets.
• In June 2020, Azelnidipine, a new calcium channel blocker, has been introduced in India by JB Chemicals and Pharmaceuticals Ltd. under the trade name Azovas. This well-known supplier specializes in Calcium Channel Blockers ranges for the management of hypertension. For the treatment of hypertension, the medication is anticipated to be very helpful for diabetologists, doctors, and cardiologists.

COVID-19 Impact on Anti-Hypertensive Drug Market

People with any form of comorbidity, including hypertension, were severely impacted by the COVID-19 pandemic. Furthermore, individuals with hypertension had to make significant adjustments to their way of life because of lockdowns and other limitations imposed to stop the virus infection from spreading. According to the American College of Cardiology's July 2020 report, early data from COVID-19 hotspots like Wuhan, Lombardy, as well as New York City indicated that people with hypertension were among the chronically ill and most hospitalized COVID-19 patients, which is expected to spur the market for anti-hypertensive medications.